<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551848</url>
  </required_header>
  <id_info>
    <org_study_id>104584</org_study_id>
    <nct_id>NCT02551848</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment</brief_title>
  <official_title>Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to study the efficacy of botulinum toxin type A (Xeomin®) injected
      utilizing kinematically-based injection parameters for the treatment of upper extremity
      essential tremor (ET). Additional objectives are to study the benefit of kinematic assessment
      tools in determining injection parameters and to study the composition of tremor using
      kinematics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kinematic tremor severity</measure>
    <time_frame>72 weeks</time_frame>
    <description>Change from pre to post-BoNT-A treatments in maximum angular tremor amplitude at the wrist in each treated arm. Angular tremor amplitude is one parameter reflecting the vectoral intensity of tremor segmented at each arm joint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical tremor severity</measure>
    <time_frame>72 weeks</time_frame>
    <description>Improvement in upper limb tremor severity as determined by an increase &gt;8 points on a standardized clinical assessment tool (Fahn-Tolosa-Marin Tremor Assessment Scale) pre and post Xeomin® injection using kinematic-determined injection parameters in both ET upper limbs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accelerometric kinematic tremor severity</measure>
    <time_frame>72 weeks</time_frame>
    <description>Change from pre and post-BoNT-A treatments in maximum log-transformed accelerometric tremor amplitude at wrist level (injected limb). Log-transformed accelerometric tremor amplitude is one parameter reflecting the non-vectoral intensity of tremor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measures</measure>
    <time_frame>72 weeks</time_frame>
    <description>Quality of life for essential tremor questionnaire is used to measure the patient's impression of change due to treatment and its change on their quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Essential Tremor</condition>
  <arm_group>
    <arm_group_label>Essential tremor treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 72 weeks. BoNT-A dose will range from 50-300 U per arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A (Xeomin®)</intervention_name>
    <arm_group_label>Essential tremor treatment</arm_group_label>
    <other_name>IncobotulinumtoxinA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting male and female participants

          -  Diagnosis of 'definite essential tremor' in accordance with the TRIG criteria
             including: ET individuals diagnosed with upper limb tremor in their motor dominant and
             non-dominant hands

          -  Stable ET medication management for the 3 month duration prior to their enrollment in
             the study

          -  Participants who are botulinum toxin naïve for tremor management

          -  Patients will be screened for pregnancy by the physician

        Exclusion Criteria:

          -  History of stroke

          -  Muscle weakness or any related compartmental muscle syndrome

          -  Smoking

          -  History of ALS or Myasthenia Gravis

          -  Offending medications (Lithium, valproate, steroids, amiodarone, beta-adrenergic
             agonists (e.g. salbutamol)

          -  Persons prescribed zonisamide

          -  History of allergic or side effect reaction to botulinum toxin

          -  Contraindications per the Xeomin® drug monograph

          -  Women reporting that they are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mandar Jog, MD</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>32758</phone_ext>
    <email>mandar.jog@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandar Jog, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>32758</phone_ext>
      <email>mandar.jog@lhsc.on.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992 Mar;56(1):80-99. Review.</citation>
    <PMID>1579114</PMID>
  </reference>
  <reference>
    <citation>Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 2010 Sep;10(5):338-44. doi: 10.1007/s11910-010-0129-z. Review.</citation>
    <PMID>20567945</PMID>
  </reference>
  <reference>
    <citation>Benito-León J, Louis ED. Essential tremor: emerging views of a common disorder. Nat Clin Pract Neurol. 2006 Dec;2(12):666-78; quiz 2p following 691. Review.</citation>
    <PMID>17117170</PMID>
  </reference>
  <reference>
    <citation>Gironell A, Kulisevsky J. Diagnosis and management of essential tremor and dystonic tremor. Ther Adv Neurol Disord. 2009 Jul;2(4):215-22. doi: 10.1177/1756285609104791.</citation>
    <PMID>21179530</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May;11(3):250-6.</citation>
    <PMID>8723140</PMID>
  </reference>
  <reference>
    <citation>Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12;56(11):1523-8.</citation>
    <PMID>11402109</PMID>
  </reference>
  <reference>
    <citation>Adler CH, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards BW, Krein-Jones K, Caviness JN. Botulinum toxin type A for treating voice tremor. Arch Neurol. 2004 Sep;61(9):1416-20.</citation>
    <PMID>15364688</PMID>
  </reference>
  <reference>
    <citation>Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, Ondo WG, Gronseth GS, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005 Jun 28;64(12):2008-20. Epub 2005 Jun 22.</citation>
    <PMID>15972843</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western University, Canada</investigator_affiliation>
    <investigator_full_name>Mandar Jog</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Movement disorders</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Kinematics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

